Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook

Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.13, $0.06 better than the analyst estimate of $0.07. Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.53 million.

2017 revenue guidance increased by $20 million, to $145-155 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
• Lumentum shares rise on analyst upgrades, AI demand outlook